[OFER] NAC: SE BUSCA ESTUDIANTE DE DOCTORADO

[efryo_hotmail.com]

***********************************************************************
OFER-TRABEC OFER-TRABEC OFER-TRABEC OFER-TRABEC OFER-TRABEC
   <http://www.rediris.es/list/sdis/ofer-trabec/> es una gentileza de:
	Centro de Información Administrativa del MAP
	FCR/UID  y
	Centro de Comunicaciones RedIRIS 
 .
Becas y Ayudas del Ministerio de Ciencia http://www.mecd.es/mecd/becas/
***********************************************************************
Servicios de Distribución de RedIRIS: http://www.rediris.es/list/sdis/
*************************************************************************

---Procedencia:
 Institución:Instituto de Investigacio Valle Hebron
 Contacto correo-e:darango@ir.vhebron.net
---
ESTUDIANTE DE DOCTORADO

Se busca:

Se buscan candidatos con un expediente académico superior a 2 para solicitar una beca predoctoral del Institut Vall d'Hebron para realizar el doctorado en el laboratorio de Oncología Molecular y Envejecimiento del Institut de Recerca Vall d'Hebron. El campo de investigación será el estudio del papel funcional de los receptores EPH y sus ligandos en el cáncer colorectal. El estudio incluirá experimentos in vitro con líneas celulares, con modelos animales y con muestras clínicas. Las técnicas a utilizar serán un amplio abanico de técnicas de biología molecular y celular, incluyendo western, Real-Time PCR, secuenciación, microarray, transfecciones, siRNA, \'screening\' de mutaciones, inmunohistoquímica, etc...

Se ofrece:

   - 14.126 € brutos anuales mas asistencia médica
   - Un año prorrogable a cuatro
   - Ambiente académico activo y estimulante

Requisitos de los candidatos:

   - Estar en posesión del título de licenciado.
   - Haber aprobado todas las asignaturas para la obtención del título de licenciado, ingeniero o arquitecto. La fecha de fin de estudios debe ser posterior al 1 de enero de 2002. Los licenciados en Medicina, Farmacia, Biología, Química o Psicología que hayan cursado la especialidad, deben haber acabado los estudios con posterioridad al 1 de enero de 1998.
   - Tener buenos conocimientos de la lengua inglesa.
   - Compromiso de matricularse en un programa de doctorado.

Contacto:

Contactar con el Dr. Diego Arango  antes del 15 de octubre de 2006.


 ----------------
Información complementaria de la oferta:
LISTA DE PUBLICACIONES DEL INVESTIGADOR PRINCIPAL

Original articles:

33.- Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr. S, Arango D. EPHB4 and survival of colorectal cancer patients. Cancer Research, 2006 In press - 

32.- Alazzouzi H, SurianoG, Guerra A, Plaja A, Espín E, Armengol M, Alhopuro P, Velho S, Shinomura Y, González-Aguilera JJ, Yamamoto H, Aaltonen L, Moreno V, Capellà G, Peinado MA, Seruca R,  Arango D, Schwartz Jr S. Tumor selection advantage of non-dominant negative p53 mutations in homozygous mdm2-snp309 colorectal cancer cells. Journal of Medical Genetics, 2006 Jul 6, [Epub ahead of print] - 

31.- Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, Schwartz S Jr. , Arango D, Mäkinen MJ, and Aaltonen LA. Serrated Carcinomas Form a Subclass of Colorectal Cancer with Distinct Molecular Basis. Oncogene, 2006 Jul 3, [Epub ahead of print] - 

30.- Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M, Imai K, Yamamoto H, Gebert JF, Díaz-Chico JC, Hofstra RM, Woerner SM, Seruca R, Schwartz Jr. S, Arango D. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene, 2006 Jul 3, [Epub ahead of print] - 

29.- Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Arango D, Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2 in human cancers confer resistance to histone deacetylase inhibition. Nature Genetics, 2006,38<5>:566-9 - 

28.- Wilson AJ, Byun DS, Smartt H, L'Italien K, Sowa Y, Arango D, Augenlicht LH and. Mariadason JM. Class I Histone deacetylases are upregulated in human colonic tumors and are linked to reduced cell differentiation in vivo and in vitro. Journal of Biological Chemistry 2006 May 12,281<19>:13548-58 - 

27.- Paroder V, Spencer SR, Paroder M, Arango D, Schwartz Jr S, Mariadason JM, Augenlicht LH, Eskandari S, and Carrasco N. Na+/monocarboxylate transport  protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences, 2006 May 9,103<19>:7270-5 - 

26.- Vanharanta S, Laiho P, Sjöberg J, Leminen A, Arola J, Aittomäki K, Karhu A, Arango D and Aaltonen LA. Global Expression Pattern of FH-deficient Fibroids. Human Molecular Genetics, 2005, 15<1>:97-103 - 

25.- Bressin C, Bourgarel-Rey V, Carré M, Pourroy B, Arango D, Braguer D and Barra Y. Decrease in c-Myc expression enhances cancer cells sensitivity to vinblastine. Anti-cancer Drugs, 2006 Feb,17<2>:181-187 - 

24.- Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr., Arango D. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Research, 2005, 65<22>:10170-3 - 

23.- Kokko A, Ylisaukko-oja S, Kiuru M, Takatalo MS, Salmikangas P, Tuimala J, Arango D, Karhu A, Aaltonen LA and Jäntti J. Modeling tumor predisposing FH mutations in yeast, effects on fumarase activity, growth phenotype and gene expression profile. International Journal of Cancer, 2006 Mar 15,118<6>:1340-5. - 

22.- Vanharanta S, Laiho P, Sjöberg J, Leminen A, Aittomäki K, Arola J, Arango D and Aaltonen LA. Distinct Expression Profiles in Fumarate Hydratase Deficient Fibroids. Oncogene, 2005, 24: 6545–6554 - 

21.- Alhopuro P, Alazzouzi H, Sammalkorpi H, Salovaara R, Järvinen H, Mecklin JP, Schwartz S Jr., Aaltonen LA and Arango D. SMAD4 and prediction of response to adjuvant therapy in colorectal cancer patients. Clinical Cancer Research, 2005,11: 6311-6316 - 

20.- Arango D, Laiho P, Kokko A, Salamrkorpi H, Järvinen H, Mecklin J-P, Salovaara R, Schwartz S Jr., Aaltonen LA. Utilization of microarray profiling to predict prognosis of patients with Dukes C colorectal cancer. Gastroenterology, 2005,129<3>:874-84 - 

19.- Kruhøffer M, Jensen JL, Laiho P, Sørensen FB, Birkenkamp-Demtroder K, Dyrskjøt L, Christensen L, Wikman FP, Arango D, Bech-Knudsen F, Lauerberg S, Aaltonen LA, and Ørntoft TF. A nine gene expression classifier predicts survival in stage II colon cancer based on microsatellite instability status. Brithish Journal of Cancer, 2005,92<12>:2240-8 - 

18.- Hienonen T, Sammalkorpi H, Enholm S, Alhopuro P, Barber TD, Lehtonen R, Nupponen NN, Lehtonen H, Salovaara R, Mecklin JP, Järvinen H, Koistinen R, Arango D, Launonen V, Vogelstein B, Karhu A, and Aaltonen LA. Mutations in two short non-coding mononucleotide repeats in most microsatellite unstable colorectal cancers. Cancer Research, 2005, 65<11>:4607-13 - 

17.- Mariadason JM, Yang W, Wilson AJ, Nicholas C, Corner GA and Arango D, Augenlicht LH. Analysis of the Genetic Reprogramming that Defines Differentiation Along the Crypt-Villus Axis. Gastroenterology, 2005,128<4>:1081-8 - 

16.- Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Schwartz Jr P, Aaltonen LA and Arango D. SMAD4 protein level as a prognostic marker in colorectal cancer. Clinical Cancer Research, 2005, 11<7>:2606-11 - 

15.- Arango D, Wilson AJ, Mariadason JM, Corner GA, Arañes MJ, Nicholas C & Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer, 2004, 91<11>:1931-46 - 

14.- Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline Mismatch Repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13<19>:2303-11 - 

13.- Khabele D, Lopez-Jones M, Yang W, Arango D, Gross S, Augenlicht LH & Goldberg GL. Tumor Necrosis Factor-&#61537, related gene response to Epothilone B. Gynecologic Oncology, 2004, 93:19-26 - 

12.- Mariadason JM, Arango D, Wilson AJ, Aranes M, Nicholas C, Corner JA and Augenlicht LH. Gene expression profiles correlating with chemoresistance of colon tumor cells to 5-fluorouracil and camptothecin. Cancer Research 2003, 63<24>:8791-8812 - 

11.- Arango D, Mariadason JM, Aranes M, Nicholas C, Corner G & Augenlicht LH. c-Myc overexpression sensitizes colon cancer cells to camptothecin-induced apoptosis. British Journal of Cancer 2003,89:1757-1765 - 

10.- Klampfer L, Huang J, Corner GA, Mariadason JM, Arango D, Sasazuki, T, Shirasawa S & Augenlicht LH. Oncogenic k-ras inhibits the expression of IFN-responsive genes through inhibition of STAT1 and STAT2 expression. Journal of Biological Chemistry 2003, 278<47>:46278-87 - 

9.- Wilson AJ, Arango D, Mariadason JM, Heerdt BG & Augenlicht LH. TR3/Nur77 in colon cancer cell apoptosis. Cancer Research 2003,63:5401-7 - 

8.- Wilson AJ, Velcich A, Arango D, Kurland AR, Shenoy SM, Pezo RC, Levsky JM Singer RH & Augenlicht LH. Novel detection and differential utilization of c-myc transcriptional block in colon cancer chemoprevention. Cancer Research 2002,62:6006-10 - 

7.- Mariadason JM, Arango D, Corner JA Aranes M, Yang W, & Augenlicht LH. A gene expression profile that defines colon cell maturation in vitro. Cancer Research 2002,62<16>:4791-804 - 

6.- Arango D, Corner GA, Wadler S, Catalano PJ & Augenlicht LH. c-myc/p53 Interaction Determines Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracil in Vitro and in Vivo. Cancer Research 2001,61<12>:4910-4915 - 

5.- Arango D, Ettarh RR, Holden G, Moriarty M & Brennan PC. BB-10010, an analogue of Macrophage Inflammatory Protein-1 alpha, protects the murine small intestine against radiation. Digestive Diseases and Sciences 2001,46<12>:2608-2614 - 

4.- Stanton MT, Ettarh R, Arango D, Tonra M & Brennan PC. Diagnostic ultrasound induces change within numbers of cryptal mitotic and apoptotic cells in small intestine. Life Sciences. 2001,68<13>:1471-5 - 

3.- Arango D, Ettarh RR & Brennan PC. Dose-effect relationship of BB-10010/MIP-1 alpha on proliferation in the murine small intestinal epithelium: single and double administration protocols. Digestive Diseases and Sciences 2000,45<12>:2306-12 - 

2.- Arango D, Ettarh RR & Brennan PC. BB-10010, an analogue of Macrophage Inflammatory Protein-1 alpha, reduces proliferation in murine small intestinal crypts. Scandinavian Journal of Gastroenterology 1999,34:68-72 - 

1.- Brennan PC, Deveraux SA, Arango D, & Ettarh RR. Cell cycle perturbations following low dose X-rays. Radiography 1999,5:111-115


Review articles:

9.- Arango D, Alhopuro P & Aaltonen LA. SMAD4 levels and allelic imbalance in 18q21 in colorectal cancer. Clinical Cancer Research 2006,12<5> 1654-1655.

8.- Mariadason JM, Arango D, & Augenlicht LH. Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resistance Updates 2004, 7<3>:209-18.

7.- Augenlicht LH, Velcich A, Klampfer L, Huang J, Corner G, Aranes M, Laboisse C, Rigas B, Lipkin M, Yang K, Shi Q, Lesser M, Heerdt B, Arango D, Yang W, Wilson A & Mariadason JM. Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. Journal of nutrition 2003, 133<7 Suppl>:2410S-2416S

6.- Mariadason JM, Augenlicht LH & Arango D. Microarray analysis in the clinical management of cancer. Hematol Oncol Clin North Am. 2003,17<2>:377-87

5.- Augenlicht LH, Mariadasom JM, Wilson AJ, Arango D, Yang WC, Heerdt BG & Velcich A. Short chain fatty acids and colon cancer. Journal of nutrition 2002, 132<12>:3804S-8S.

4.- Augenlicht LH, Wadler S & Arango D. Clinical Response to Fluorouracil and p53. New England Journal of Medicine 2001,345<14>:1065-6

3.- Arango D & Augenlicht LH. New approaches to colorectal cancer treatment. In: Recent Research Developments in Cancer 2001, 3:385-395

2.- Arango D, Ettarh RR & Brennan PC. Early effects of low let ionising radiation on the small intestine: a review. Radiography Ireland 1999,3:17-19

1.- Arango D, Ettarh RR & Brennan PC. Ionising radiation and its effects on living matter: a review. Radiography Ireland 1998,2:63-64


----------------------------------------------------
Para darse de baja OFER-TRABEC pincha y envia el siguiente url
mailto:OFER-TRABEC-signoff-request@listserv.rediris.es
----------------------------------------------------